Trial Profile
A Randomized Two-Arm Phase II Study of Trametinib Alone and in Combination with GSK2141795 in Patients with Advanced Uveal Melanoma (NCI #9445)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Trametinib (Primary) ; Uprosertib (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 25 Jan 2018 Status changed from active, no longer recruiting to completed.
- 07 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 30 Sep 2016 Planned number of patients changed from 80 to 60.